Human Genome Sciences: Novel Product Line, Significant Debt Reduction
George Chadwick submits:
Much of this research on Human Genome Sciences Inc. (HGSI) was performed just prior to the company’s earnings release on March 2, 2010, in large part to help decide whether or not to continue to hold after an 80% gain (now a 90% gain) in one of our portfolios.
It is interesting to note that the language used in HGSI’s earnings report very closely matched what was unearthed during the research (see below). This should exemplify the usefulness of doing the research!
